Trending News

How Are Family Offices Building Smarter Wealth? Structural Alpha (11 Examples)

DOJ Rule Restricting Sensitive Data Transfers Takes Effect

The Trump Administration’s Diversity, Equity, and Inclusion (DEI) Executive Orders: A Brief Primer

Trump Administration Announces "Reciprocal" Tariffs

What Every Multinational Company Should Know About … The Global and Reciprocal Tariffs Announcement

Blockading the Ports: U.S. Imposes 10% Global Tariff; Higher Reciprocal Tariff Rates by Country

Fifth Circuit Court of Appeals Negates Ruling on Federal Contractor Minimum Wage

New Executive Order Rescinds the $17.75 Per Hour Federal Contractor Minimum Wage

Medicare Telehealth Gets Another Temporary Lifeline – Will Congress Make it Permanent?

BREAKING: District Court Restores Status Quo Ante At NLRB

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards
Posted On Friday, February 21, 2025
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
Posted On Friday, February 21, 2025
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
Posted On Thursday, February 20, 2025
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
Posted On Thursday, February 20, 2025
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
Posted On Thursday, February 20, 2025
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
Posted On Thursday, February 20, 2025
Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders
Posted On Thursday, February 20, 2025
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Posted On Thursday, February 20, 2025
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Posted On Thursday, February 20, 2025
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
Posted On Thursday, February 20, 2025
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
Posted On Thursday, February 20, 2025
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Posted On Thursday, February 20, 2025
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Posted On Thursday, February 20, 2025
NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today
Posted On Thursday, February 20, 2025
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Posted On Thursday, February 20, 2025
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split
Posted On Thursday, February 20, 2025
Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River™ Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)
Posted On Thursday, February 20, 2025
Women Founders Face Persistent Funding Gaps—Philadelphia Event Aims to Accelerate Action
Posted On Thursday, February 20, 2025
COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
Posted On Thursday, February 20, 2025
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Posted On Thursday, February 20, 2025
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
Posted On Thursday, February 20, 2025
Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission
Posted On Thursday, February 20, 2025
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
Posted On Thursday, February 20, 2025
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
Posted On Thursday, February 20, 2025
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Posted On Thursday, February 20, 2025

Print